<DOC>
	<DOC>NCT02596724</DOC>
	<brief_summary>Prospective observational registry that links results of the genomic and other molecular testing to treatment response and survival measures in patients who have been diagnosed with breast cancer and who are targeted for neo-adjuvant therapy. Analysis includes how tests impact treatment decisions and outcomes.</brief_summary>
	<brief_title>TME Neoadjuvant Breast Registry</brief_title>
	<detailed_description>Physicians will order tests on patients as part of standard of care; they will report whether test results influenced: selection between standard therapies or a clinical trial; offered insight into mid therapy treatment changes; or helped physicians determine what therapy to offer patients who do not have a complete pathologic response. Patient demographics, diagnosis, type of treatment, surgery and pathologic results will be recorded. Patients will be followed for 5 years. Recurrence and survival data will be recorded. Participating sites will submit de-identified patient data via electronic case report forms (eCRFs) into a secure study website. All patients are required to sign an Informed Consent Form. All investigators and staff will have Human Subject Protection Training.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients with histologically proven invasive breast cancer who have started or are scheduled to start neoadjuvant chemotherapy or endocrine therapy Ages 1890 Written informed consent Patients who have had excisional biopsy or axillary dissection Patients with confirmed metastatic disease Patients who have had recent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant therapy for breast cancer</keyword>
</DOC>